Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases
Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases.